Global Hospital Acquired Infections Therapeutic Market Size, Share, Growth Analysis Report - Forecast 2034

Hospital Acquired Infections Therapeutic Market: Industry Perspective

The global hospital acquired infections therapeutic market size was worth around USD 12.52 Billion in 2024 and is predicted to grow to around USD 26.05 Billion by 2034 with a compound annual growth rate (CAGR) of roughly 7.6% between 2025 and 2034. The report analyzes the global hospital acquired infections therapeutic market's drivers, restraints/challenges, and the effect they have on the demands during the projection period. In addition, the report explores emerging opportunities in the hospital acquired infections therapeutic industry.

Request Free Sample

Global Hospital Acquired Infections Therapeutic Market: Overview

Hospital Acquired Infections Therapeutic Market is also known as Healthcare-associated Infections. It is one of the leading causes of death worldwide. It can be acquired in hospital, nursing home, rehabilitation facility, outpatient clinic, etc. Hospital Acquired Infections (HAIs) are caused due to fungal, viral, and bacterial infections. Poor maintenance of hygiene and growing complacency among healthcare workers are the factors leading to HAIs.

Key Insights

• As per the analysis shared by our research analyst, the global hospital acquired infections therapeutic market is estimated to grow annually at a CAGR of around 7.6% over the forecast period (2025-2034).
• Regarding revenue, the global hospital acquired infections therapeutic market size was valued at around USD 12.52 Billion in 2024 and is projected to reach USD 26.05 Billion by 2034.
• The hospital acquired infections therapeutic market is projected to grow at a significant rate due to Growing incidence of HAIs and antibiotic-resistant pathogens fuels demand for effective treatments. Hospital infrastructure improvements and government support boost the market.
• Based on Infection Type, the Urinary Tract Infections segment is expected to lead the global market.
• On the basis of Drug Class, the Antibiotics segment is growing at a high rate and will continue to dominate the global market.
• Based on the Pathogen Type, the Bacterial segment is projected to swipe the largest market share.
• By End-user, the Hospitals segment is expected to dominate the global market.
• Based on region, North America is predicted to dominate the global market during the forecast period.

Global Hospital Acquired Infections Therapeutic Market: Growth Factors

Increase in number of hospital admitted patients and improved diagnostics capable of differentiating strains of microbes has resulted in increase of Hospital Acquired Infections worldwide. The rising geriatric population, which is more vulnerable to such ailments, is also driving the market growth. The rise in number of pipeline drugs specifically developing for the hospital acquired infections and an increase in R&D investments expected to boost the market growth over the forecast period. Improvement in the healthcare infrastructure is also likely to boost the market of Hospital Acquired Infections Therapeutic globally.

Hospital Acquired Infections Therapeutic Market: Report Scope

Global Hospital Acquired Infections Therapeutic Market: Segmentation

The Hospital Acquired Infections Therapeutic Market is segmented based on drug class, infection type and region.

On the basis of drug class, the Hospital Acquired Infections Therapeutic Market is segmented into Antibacterial Drugs, Antiviral Drugs, Antifungal Drugs. In 2024, the Antibacterial Drugs dominated the market as most of the cases were caused due to bacteria and thus treated with antibacterial drugs.

Based on infection type, the Hospital Acquired Infections Therapeutic Market is bifurcated into Urinary Tract Infections, Ventilator-associated Pneumonia, Surgical Site Infections, Bloodstream Infections, Other Hospital Infections. In 2024, the Surgical Site Infections held the maximum number of shares due to the rising number of surgical procedures and cases.

By Pathogen Type, the global hospital acquired infections therapeutic market is split into Bacterial, Viral, Fungal.

In terms of End-user, the global hospital acquired infections therapeutic market is categorized into Hospitals, Clinics, Ambulatory Surgical Centers.

Global Hospital Acquired Infections Therapeutic Market: Regional Analysis

Europe dominated the market for Hospital Acquired Infections due to the high prevalence of HAIs in European countries and increasing approvals and launch of novel HAI therapeutic drugs in the region. Furthermore, higher accessibility of novel hospital-acquired infection therapeutics in the European is further expected to drive the growth of the region.

In Asia Pacific, the market for HAIs therapeutics is anticipated to show significant growth during the forecast period due to factors such as increasing prevalence of chronic diseases in emerging economies such as India and China which has led to increased hospitalizations.

Hospital Acquired Infections Therapeutic Market: Competitive Analysis

The report provides a company market share analysis to give a broader overview of the key market players. In addition, the report also covers key strategic developments of the market, including acquisitions & mergers, new product launches, agreements, partnerships, collaborations & joint ventures, research & development, and regional expansion of major participants involved in the hospital acquired infections therapeutic market on a global and regional basis.

The global hospital acquired infections therapeutic market is dominated by players like:

• Merck & Co. Inc.
• Pfizer Inc.
• Bayer AG
• GlaxoSmithKline Plc.
• Daiichi Sankyo Company Limited
• AbbVie Inc.
• Abbott Laboratories
• F. Hoffmann-La Roche Ltd.
• Cubist Pharmaceuticals Inc.
• and Allergan Plc. among others

The global hospital acquired infections therapeutic market is segmented as follows;

By Infection Type

• Urinary Tract Infections
• Surgical Site Infections
• Bloodstream Infections
• Pneumonia
• Others

By Drug Class

• Antibiotics
• Antifungals
• Antivirals

By Pathogen Type

• Bacterial
• Viral
• Fungal

By End-user

• Hospitals
• Clinics
• Ambulatory Surgical Centers

By Region

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• The Middle East & Africa
  • Saudi Arabia
  • UAE
  • Egypt
  • Kuwait
  • South Africa
  • Rest of the Middle East & Africa
• Latin America
  • Brazil
  • Argentina
  • Rest of Latin America